Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333067 | 0.86 | AR (0.41) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL221854 | 0.83 | AR (0.42) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL1365870 | 0.83 | AR (0.36) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL31467810 | 0.81 | TRPV4 (0.35) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL4085468 | 0.79 | AR (0.36) | ARTRPV4 | |
| SCHEMBL3824893 | 0.79 | TAAR1 (0.36) | DAO | |
| SCHEMBL1363736 | 0.79 | AR (0.44) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL14863560 | 0.75 | AR (0.38) | ARCYP11B1CYP11B2ESR1ESR2 | |
| SCHEMBL3717737 | 0.75 | AR (0.41) | ARCYP11B1CYP11B2TRPV4DAO | |
| SCHEMBL1365376 | 0.73 | AR (0.46) | ARCYP11B1CYP11B2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2260028-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010118287-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118287-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| WO-2009105214-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | AR 1/4885CYP11B1 39/4885CYP11B2 29/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885CYP11B1 41/4885CYP11B2 26/4885 |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | AR, SHBG, IGF1R | AR 1/4885CYP11B1 42/4885CYP11B2 29/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885CYP11B1 41/4885CYP11B2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.